Certificate of Agreement

This Certificate is signed by

OnDosis AB
Pepparedsleden 1
SE-431 83 Mölndal
Sweden

(hereinafter called „OnDosis")

and

AET Pharma US, Inc.
9841 Washingtonian Boulevard Suite 200
Gaithersburg, MD 20878, USA

(hereinafter called „AET")

In connection with OnDosis' submission for certification by FCC for future devices, under development by OnDosis, and intended for future commercialisation by AET as a component of products commercialised as drug/device combinations, OnDosis and AET hereby confirms the following accountabilities regarding the creation of the IFU (User manual) and commercial pictures of products based on the OnDosis Dosage manager ODM01 including the Control Unit CU01:

Background

The OnDosis Dosage manager ODM01 including the Control Unit CU01 will be used in combination with various drugs developed, or under development, by AET. The various drugs will be distributed under different brands and require different dosing schemes. As a consequence, various IFU's and photos will be created by the legal manufacturer of the drug/device combination products AET, based on the generic IFU created by OnDosis and shared with the FCC.

Cooperation agreement and key areas of responsibility

The cooperation between OnDosis and AET is regulated in a specific cooperation agreement signed August 7th 2020. Under the cooperation agreement, the following responsibilities are defined:

OnDosis develops and manufactures Dosage Manager devices for combination with drugs.

OnDosis cooperate with AET, and the OnDosis Dosage Manager ODM01 including the control unit CU1 will be used in combination with several different types of drugs manufactured by AET, and will be commercialised as drug/device combination products.

Drugs that benefit from being combined with the Dosage Manager are drugs that require flexible, precise, and individual dosing, such as for example stimulants in ADHD.

In the FDA regulations the OnDosis Dosage Manager is defined as the "device constituent part of a Combination product". This means that according to the FDA, the device itself is not the product.

AET will base the drug specific IFU on the OnDosis generic IFU and add the following information:

- Drug name (Brand)
- Dosing scheme
- Warnings and Cautions
- Other Medicine/ Drug specific features
- Legal manufacturer name
- Contact information to Legal manufacturer
- Pictures of the product with the Medicine/ Drug name printed on the device

Due to the many different variants of drugs and dosing schemes, the Control unit CU1 (including the radio) will be configurated to allow only to dispense a specific drug.

The Device (CU01) itself will be identical from hardware design perspective. However, the actual dosing scheme will be configurated in the embedded software and the labelling (Legal manufacturer, drug type, etc.).

This means that the pictures of the product and the IFU (User manual) will be created by AET when the product is ready to be placed on the market. The IFU (User manual) also includes important information about the drug, dosing scheme and legal manufacturer. The drug related information in the IFU is vital for the user and will be developed by AET

The parties hereby confirms what is stated in this Certificate of Agreement

Gaithersburg, 08.30.2022

AET Pharma US, Inc.

Elwira Baldyga

Digital unterschrieben von Elwira Baldyga
Datum: 2022.09.08 23:28:01 +02'00'

.....
Elwira Baldyga
Director

Mölndal, 11 SEPT 2022

OnDosis AB

.....
Martin Olovsson
CEO and Co-founder